Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe

Authors:

Abstract
The high cost of cancer medicines to patients and health systems globally is a public health challenge. Spending on cancer drugs is projected to grow to $100 billion in the US and $50 billion in Europe by 2022.1 The financial toxicity of costly cancer medicines may include medication nonadherence and negative patient outcomes.2-4 This challenge of paying for cancer therapies likely will be magnified in the coming years by the effect of the ongoing COVID-19 pandemic on individual finances and national economies.5

This publication has 17 references indexed in Scilit: